Lupus & antiphospholipid syndrome
Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice
Authors' conclusion
Overall satisfaction, satisfaction with via of administration, and satisfaction with the time taken to receive BEL were higher for SQ BEL treatment.
Study context
- Population
- Stable SLE patients (EULAR/ACR 2019) on SQ belimumab (BEL) with previous intravenous (IV) BEL, Catalonia
- Participants
- 27 patients
- Exposure
- Switch from IV to SQ belimumab
- SQ BELn = 27
- Outcome
- Satisfaction with SQ BEL therapy (RASQ-SQ modified for BEL)
Methodological detailsmulticentre, 7 reference centres in Catalonia
- Multicentre
- 7 reference centres in Catalonia
Main finding
As reported in the abstract
Satisfaction with SQ BEL
Confidence in SQ BEL
84%
SQ BEL convenient or very convenient
85.2%
Felt they had gained time with the change
85%
Would recommend SQ injection to other patients
89%
Observational data: associations, not effects.
Further findings
Disease activity (mean SLEDAI) and remission rates
- Remain stable after switching
Baseline characteristics · mean baseline
- Mean baseline SLEDAI (SD 2.4)
- 2.96
- SLICC score (SD 0.88)
- 0.67
- Median time on IV BEL before switching
- 21 months
Original publication
Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice. Lupus. Published 6 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →